FDA warned usaquickmeds.com for selling unapproved and misbranded opioids and benzodiazepines online without prescriptions.
What happened
FDA reviewed the website www.usaquickmeds.com and found it offered tapentadol, tramadol, alprazolam, and lorazepam for sale to U.S. consumers. FDA said the site sold these prescription drugs without a prescription and without FDA-approved applications, making them unapproved and misbranded. The letter cites website claims that the products treat pain, anxiety, and other conditions.
What FDA found
The website sold tapentadol, tramadol, alprazolam, and lorazepam as new drugs without FDA-approved applications.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The prescription drugs' labeling did not include adequate directions for use by a layperson.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The website offered prescription drugs for sale without requiring a prescription.
FD&C Act §§ 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The website caused misbranded drugs to be introduced into interstate commerce by offering them for sale to U.S. consumers.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs to U.S. consumers. It must reply in writing within 15 working days describing corrective steps and how it will prevent recurrence.
Who should pay attention
- online pharmacies selling to U.S. consumers
- companies that fulfill or distribute prescription drugs
- regulatory teams monitoring internet drug promotion
This is a summary. Read the original letter on fda.gov.